Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 18(5): e0285672, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37192198

RESUMO

Human cytomegalovirus causes severe diseases in children (by congenital infection) and immunocompromised patients. Treatment with antiviral agents, such as ganciclovir, is limited by their toxicity. In this study, we investigated the effectiveness of a fully human neutralizing monoclonal antibody to inhibit human cytomegalovirus infection and viral cell-to-cell spread. We isolated a potent neutralizing antibody, EV2038 (IgG1 lambda), targeting human cytomegalovirus glycoprotein B using Epstein-Barr virus transformation. This antibody inhibited human cytomegalovirus infection by all four laboratory strains and 42 Japanese clinical isolates, including ganciclovir-resistant isolates, with a 50% inhibitory concentration (IC50) ranging from 0.013 to 0.105 µg/mL, and 90% inhibitory concentration (IC90) ranging from 0.208 to 1.026 µg/mL, in both human embryonic lung fibroblasts (MRC-5) and human retinal pigment epithelial (ARPE-19) cells. Additionally, EV2038 prevented cell-to-cell spread of eight clinical viral isolates, with IC50 values ranging from 1.0 to 3.1 µg/mL, and IC90 values ranging from 13 to 19 µg/mL, in ARPE-19 cells. EV2038 recognized three discontinuous sequences on antigenic domain 1 of glycoprotein B (amino acids 549-560, 569-576, and 625-632), which were highly conserved among 71 clinical isolates from Japan and the United States. Pharmacokinetics study in cynomolgus monkeys suggested the potential efficacy of EV2038 in vivo, the concentration of which in serum remained higher than the IC90 values of cell-to-cell spread until 28 days after intravenous injection of 10 mg/kg EV2038. Our data strongly support EV2038 as a promising candidate and novel alternative for the treatment of human cytomegalovirus infection.


Assuntos
Infecções por Citomegalovirus , Infecções por Vírus Epstein-Barr , Criança , Humanos , Epitopos , Anticorpos Antivirais , Anticorpos Monoclonais/farmacologia , Herpesvirus Humano 4 , Proteínas do Envelope Viral , Anticorpos Neutralizantes , Ganciclovir
2.
Antiviral Res ; 201: 105297, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-35341809

RESUMO

Monoclonal antibody therapy is a promising option for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and a cocktail of antibodies (REGN-COV) has been administered to infected patients with a favorable outcome. However, it is necessary to continue generating novel sets of monoclonal antibodies with neutralizing activity because viral variants can emerge that show resistance to the currently utilized antibodies. Here, we isolated a new cocktail of antibodies, EV053273 and EV053286, from peripheral blood mononuclear cells derived from convalescent patients infected with wild-type SARS-CoV-2. EV053273 exerted potent antiviral activity against the Wuhan wild-type virus as well as the Alpha and Delta variants in vitro, whereas the antiviral activity of EV053286 was moderate, but it had a wide-range of suppressive activity on the wild-type virus as well as the Alpha, Beta, Delta, Kappa, Omicron BA.1, and BA.2 variants. With the combined use of EV053273 and EV053286, we observed similar inhibitory effects on viral replication as with REGN-COV in vitro. We further assessed their activity in vivo by using a mouse model infected with a recently established viral strain with adopted infectious activity in mice. Independent experiments revealed that the combined use of EV053273 and EV053286 or the single use of each monoclonal antibody efficiently blocked infection in vivo. Together with data showing that these two monoclonal antibodies could neutralize REGN-COV escape variants and the Omicron variant, our findings suggest that the EV053273 and EV053286 monoclonal antibody cocktail is a novel clinically applicable therapeutic candidate for SARS-CoV-2 infection.


Assuntos
Antineoplásicos Imunológicos , Tratamento Farmacológico da COVID-19 , Anticorpos Monoclonais , Anticorpos Monoclonais Humanizados , Anticorpos Neutralizantes , Anticorpos Antivirais , Antivirais/farmacologia , Antivirais/uso terapêutico , Combinação de Medicamentos , Humanos , Leucócitos Mononucleares , SARS-CoV-2 , Glicoproteína da Espícula de Coronavírus
3.
J Exp Bot ; 55(402): 1577-85, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15208343

RESUMO

The capability to utilize different forms of nitrogen (N) by sorghum (Sorghum bicolor), rice (Oryza sativa), maize (Zea mays), and pearl millet (Pennisetum glaucum) was determined in pot experiments. Seedlings were grown for 21 d without N, or with 500 mg N kg(-1) soil applied as ammonium nitrate, rice bran or a mixture of rice bran and straw. No treatment-dependent changes of root length, surface area, and fractal dimension were observed. Shoot growth and N uptake in maize and pearl millet correlated with the inorganic N (ammonium and nitrate) concentration in the soil, suggesting that these species depend upon inorganic N uptake. On the other hand, shoot growth and N uptake patterns in sorghum and rice indicated that these two species could compensate low inorganic N levels in the organic material treatments by taking up organic N (proteins). Analysis of N uptake rates in solution culture experiments confirmed that sorghum and rice roots have higher capabilities to absorb protein N than maize and pearl millet.


Assuntos
Nitratos/metabolismo , Nitrogênio/metabolismo , Oryza/crescimento & desenvolvimento , Panicum/crescimento & desenvolvimento , Sorghum/crescimento & desenvolvimento , Zea mays/crescimento & desenvolvimento , Cinética , Compostos Nitrosos/metabolismo , Fosfatos/metabolismo , Brotos de Planta/crescimento & desenvolvimento , Solo/análise , Especificidade da Espécie , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...